ArticleCellular and molecular gastroenterology and hepatology2024
Antagonism Between Gut Ruminococcus gnavus and Akkermansia muciniphila Modulates the Progression of Chronic Hepatitis B.
Article in Cellular and molecular gastroenterology and hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Gut microbiota composition in responders vs. non-responders with hepatocellular carcinoma under ICI therapy: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Exercise Training Transiently Increases Gut Microbiota Diversity and Short-Chain Fatty Acid Production in a Diet-Dependent Manner in Healthy Adults.Microorganisms · 2026Article
- HBV and the Microbiome-PubMed Database Literature Review.Infectious disease reports · 2026Review
- A Study on the Association Between Treatment Response to Atezolizumab Plus Bevacizumab Combination Therapy for Advanced Hepatocellular Carcinoma and Gut Microbiota.Microorganisms · 2026Article
- Gut Microbiota-Derived Propionate Governs Hepatic N2 Neutrophils in Wilson's Disease.Cellular and molecular gastroenterology and hepatology · 2026Article
- Causal relationships among gut microbiota, plasma metabolites, and hepatocellular carcinoma: A mediation Mendelian randomization study.Medicine · 2025Article
- A novel chronic hepatitis B mouse model with immune activation and liver fibrosis.Microbiology spectrum · 2025Article
- Machine learning algorithms reveal gut microbiota signatures associated with chronic hepatitis B-related hepatic fibrosis.World journal of gastroenterology · 2025Article
- Ruminococcus gnavus in the gut: driver, contributor, or innocent bystander in steatotic liver disease?The FEBS journal · 2025Review
- Akkermansia muciniphila: biology, microbial ecology, host interactions and therapeutic potential.Nature reviews. Microbiology · 2025Review
- The gut-brain axis underlying hepatic encephalopathy in liver cirrhosis.Nature medicine · 2025Article
- Gut microbiota in liver diseases: initiation, development and therapy.Frontiers in medicine · 2025Review
- Colonization byFrontiers in immunology · 2025Article
- Species-level enterosignatures predict clinical phenotypes in chronic hepatitis B and causal triangulation of gut-metabolite-CHB interactions.Frontiers in microbiology · 2025Article
- Expert Consensus on the Prevention and Treatment of Chronic Hepatitis B in Children.Infectious diseases & immunity · 2024Article
- [Research progress on clinical antiviral treatment of chronic hepatitis B in children].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsA long immune-tolerant (IT) phase lasting for decades and delayed HBeAg seroconversion (HBe-SC) in patients with chronic hepatitis B (CHB) increase the risk of liver diseases. Early entry into the immune-active (IA) phase and HBe-SC confers a favorable clinical outcome with an unknown mechanism. We aimed to identify factor(s) triggering IA entry and HBe-SC in the natural history of CHB.
methodsTo study the relevance of gut microbiota evolution in the risk of CHB activity, fecal samples were collected from CHB patients (n = 102) in different disease phases. A hepatitis B virus (HBV)-hydrodynamic injection (HDI) mouse model was therefore established in several mouse strains and germ-free mice, and multiplatform metabolomic and bacteriologic assays were performed.
resultsRuminococcus gnavus was the most abundant species in CHB patients in the IT phase, whereas Akkermansia muciniphila was predominantly enriched in IA patients and associated with alanine aminotransferase flares, HBeAg loss, and early HBe-SC. HBV-HDI mouse models recapitulated this human finding. Increased cholesterol-to-bile acids (BAs) metabolism was found in IT patients because R gnavus encodes bile salt hydrolase to deconjugate primary BAs and augment BAs total pool for facilitating HBV persistence and prolonging the IT course. A muciniphila counteracted this activity through the direct removal of cholesterol. The secretome metabolites of A muciniphila, which contained small molecules structurally similar to apigenin, lovastatin, ribavirin, etc., inhibited the growth and the function of R gnavus to allow HBV elimination.
conclusionsR gnavus and A muciniphila play opposite roles in HBV infection. A muciniphila metabolites, which benefit the elimination of HBV, may contribute to future anti-HBV strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.